1. Home
  2. TRST vs OMER Comparison

TRST vs OMER Comparison

Compare TRST & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TrustCo Bank Corp NY

TRST

TrustCo Bank Corp NY

HOLD

Current Price

$43.10

Market Cap

782.5M

Sector

Finance

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$10.35

Market Cap

788.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRST
OMER
Founded
1902
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
782.5M
788.4M
IPO Year
1994
2008

Fundamental Metrics

Financial Performance
Metric
TRST
OMER
Price
$43.10
$10.35
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$32.50
AVG Volume (30 Days)
119.7K
702.1K
Earning Date
04-20-2026
05-14-2026
Dividend Yield
3.52%
N/A
EPS Growth
26.46
N/A
EPS
3.25
N/A
Revenue
N/A
$29,868,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.28
N/A
Revenue Growth
N/A
N/A
52 Week Low
$27.18
$2.95
52 Week High
$48.45
$17.65

Technical Indicators

Market Signals
Indicator
TRST
OMER
Relative Strength Index (RSI) 45.03 37.36
Support Level $41.96 $9.31
Resistance Level $45.17 $12.06
Average True Range (ATR) 1.19 0.47
MACD -0.02 -0.10
Stochastic Oscillator 36.63 17.83

Price Performance

Historical Comparison
TRST
OMER

About TRST TrustCo Bank Corp NY

Trustco Bank Corp N Y is a savings and loan holding company. The core part of a business consists of accepting deposits and making loans and investments. It offers a range of both personal and business banking services. The company's product includes savings accounts; retirement accounts; money market account; mortgages; building loans; auto loans and others. The company based on only one business segment, that of community banking. TrustCo lends in the geographic territory of its branch locations in New York, Florida, Massachusetts, New Jersey, and Vermont.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: